Works matching IS 01676997 AND DT 2013 AND VI 31 AND IP 3

Results: 39

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 707, doi. 10.1007/s10637-012-9866-y

By:

Wang-Gillam, Andrea;
Plambeck-Suess, Stacey;
Goedegebuure, Peter;
Simon, Peter;
Mitchem, Jonathan;
Hornick, John;
Sorscher, Steven;
Picus, Joel;
Suresh, Rama;
Lockhart, Albert;
Tan, Benjamin;
Hawkins, Williams

Publication type:

Article

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Published in:

2013

By:

Morris, Don;
Feng, Xiaolan;
DiFrancesco, Lisa;
Fonseca, Kevin;
Forsyth, Peter;
Paterson, Alexander;
Coffey, Matt;
Thompson, Brad

Publication type:

Journal Article

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Published in:

2013

By:

Massard, Christophe;
Margetts, Jane;
Amellal, Nadia;
Drew, Yvette;
Bahleda, Ratislav;
Stevens, Peter;
Armand, Jean;
Calvert, Hilary;
Soria, Jean;
Coronado, Cinthya;
Kahatt, Carmen;
Alfaro, Vicente;
Siguero, Mariano;
Fernández-Teruel, Carlos;
Plummer, Ruth

Publication type:

Journal Article

Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Published in:

2013

By:

Massard, Christophe;
Margetts, Jane;
Amellal, Nadia;
Drew, Yvette;
Bahleda, Ratislav;
Stephens, Peter;
Armand, Jean;
Calvert, Hilary;
Soria, Jean;
Coronado, Cinthya;
Kahatt, Carmen;
Alfaro, Vicente;
Siguero, Mariano;
Fernández-Teruel, Carlos;
Plummer, Ruth

Publication type:

Journal Article

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 734, doi. 10.1007/s10637-012-9880-0

By:

Awada, A.;
Dumez, H.;
Hendlisz, A.;
Wolter, P.;
Besse-Hammer, T.;
Uttenreuther-Fischer, M.;
Stopfer, P.;
Fleischer, F.;
Piccart, M.;
Schöffski, P.

Publication type:

Article

A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 616, doi. 10.1007/s10637-012-9841-7

By:

Hong, Yong;
Kim, Kyu-pyo;
Lim, Hyeong-Seok;
Bae, Kyun-Seop;
Ryu, Min-Hee;
Lee, Jae-Lyun;
Chang, Heung;
Kang, Yoon-Koo;
Kim, Hyeyoun;
Kim, Tae

Publication type:

Article

A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [F]fluorothymidine-positron emission tomography.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 506, doi. 10.1007/s10637-012-9874-y

By:

Lee, Seung;
Kim, Eun;
Lee, Haeng;
Kim, Seog;
Oh, Seung;
Ryu, Jin;
Moon, Dae;
Ahn, Jin-Hee;
Kim, Sang-We

Publication type:

Article

Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 525, doi. 10.1007/s10637-012-9883-x

By:

Ali, Amna;
Sidorova, Tatyana;
Matesic, Diane

Publication type:

Article

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 567, doi. 10.1007/s10637-012-9896-5

By:

Ma, Brigette;
Lui, Vivian;
Hui, Connie;
Lau, Cecilia;
Wong, Chi-Hang;
Hui, Edwin;
Ng, Margaret;
Tsao, S.;
Li, Yan;
Chan, Anthony

Publication type:

Article

Determinants of patient screen failures in Phase 1 clinical trials.

Published in:

2013

By:

Mckane, Alexandra;
Sima, Chao;
Ramanathan, Ramesh;
Jameson, Gayle;
Mast, Cathy;
White, Erica;
Fleck, Sharon;
Downhour, Molly;
Hoff, Daniel;
Weiss, Glen

Publication type:

Report

Erratum to: Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.

Published in:

2013

By:

Asahina, Hajime;
Nokihara, Hiroshi;
Yamamoto, Noboru;
Yamada, Yasuhide;
Tamura, Yosuke;
Honda, Kazunori;
Seki, Yoshitaka;
Tanabe, Yuko;
Shimada, Hitoshi;
Shi, Xiaojin;
Tamura, Tomohide

Publication type:

Correction Notice

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 642, doi. 10.1007/s10637-012-9848-0

By:

Trarbach, Tanja;
Przyborek, Marta;
Schleucher, Norbert;
Heeger, Steffen;
Lüpfert, Christian;
Vanhoefer, Udo

Publication type:

Article

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 714, doi. 10.1007/s10637-012-9876-9

By:

Gordon, Michael;
Rosen, Lee;
Mendelson, David;
Ramanathan, Ramesh;
Goldman, Jonathan;
Liu, Lili;
Xu, Yan;
Gerson, Stanton;
Anthony, Stephen;
Figg, William;
Spencer, Shawn;
Adams, Bonne;
Theuer, Charles;
Leigh, Bryan;
Weiss, Glen

Publication type:

Article

The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 535, doi. 10.1007/s10637-012-9884-9

By:

Venkateswaran, Amudhan;
Friedman, David;
Walsh, Alexandra;
Skala, Melissa;
Sasi, Soumya;
Rachakonda, Girish;
Crooks, Peter;
Freeman, Michael;
Sekhar, Konjeti

Publication type:

Article

EGFR and HER2 inhibition in pancreatic cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 558, doi. 10.1007/s10637-012-9891-x

By:

Walsh, Naomi;
Kennedy, Susan;
Larkin, AnneMarie;
Corkery, Brendan;
O'Driscoll, Lorraine;
Clynes, Martin;
Crown, John;
O'Donovan, Norma

Publication type:

Article

Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 516, doi. 10.1007/s10637-012-9875-x

By:

Gialeli, Ch.;
Theocharis, A.;
Kletsas, D.;
Tzanakakis, G.;
Karamanos, N.

Publication type:

Article

Characterization of a membrane-active anti-tumor agent, UA8967.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 576, doi. 10.1007/s10637-012-9901-z

By:

Dorr, Robert;
Samulitis, Betty;
Wisner, Lee;
Han, Haiyong;
Zhao, Yu;
Beroza, Paul;
Damodaran, Komath;
Igarashi, Suzu;
Landowski, Terry;
Hoff, Daniel

Publication type:

Article

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 669, doi. 10.1007/s10637-012-9857-z

By:

Hudes, Gary;
Tagawa, Scott;
Whang, Young;
Qi, Ming;
Qin, Xiang;
Puchalski, Thomas;
Reddy, Manjula;
Cornfeld, Mark;
Eisenberger, Mario

Publication type:

Article

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 599, doi. 10.1007/s10637-012-9833-7

By:

Hasegawa, Yoshikazu;
Okamoto, Isamu;
Takezawa, Ken;
Miyazaki, Masaaki;
Tsurutani, Junji;
Yonesaka, Kimio;
Morinaga, Ryotaroh;
Tsuya, Asuka;
Terashima, Masaaki;
Kudoh, Toshihiro;
Azuma, Koichi;
Kurata, Takayasu;
Nishikawa, Tatsuyuki;
Fukuoka, Masahiro;
Nishimura, Yasumasa;
Nakagawa, Kazuhiko

Publication type:

Article

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 751, doi. 10.1007/s10637-012-9885-8

By:

Jonge, Maja;
Hamberg, Paul;
Verweij, Jaap;
Savage, Shawna;
Suttle, A.;
Hodge, Jeffrey;
Arumugham, Thangam;
Pandite, Lini;
Hurwitz, Herbert

Publication type:

Article

Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Published in:

2013

By:

Marchetti, Serena;
Pluim, Dick;
Eijndhoven, Monique;
Tellingen, Olaf;
Mazzanti, Roberto;
Beijnen, Jos;
Schellens, Jan

Publication type:

Correction Notice

Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 780, doi. 10.1007/s10637-012-9903-x

By:

Rimondi, Erika;
Secchiero, Paola;
Melloni, Elisabetta;
Grill, Vittorio;
Zauli, Giorgio

Publication type:

Article

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 653, doi. 10.1007/s10637-012-9850-6

By:

Nwankwo, Nwabundo;
Zhang, Zhe;
Wang, Ting;
Collins, Connie;
Resta, Lee;
Ermisch, Sabine;
Day, Jeannette;
Decker, Rodney;
Kornberg, Lori;
Nicol, Steven;
Thornton, Donald;
Armstrong, Deborah;
Carducci, Michael

Publication type:

Article

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 685, doi. 10.1007/s10637-012-9863-1

By:

Mortazavi, Amir;
Ling, Yonghua;
Martin, Ludmila;
Wei, Lai;
Phelps, Mitch;
Liu, Zhongfa;
Harper, Erica;
Ivy, S.;
Wu, Xin;
Zhou, Bing-Sen;
Liu, Xiyong;
Deam, Deidre;
Monk, J.;
Hicks, William;
Yen, Yun;
Otterson, Gregory;
Grever, Michael;
Bekaii-Saab, Tanios

Publication type:

Article

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 696, doi. 10.1007/s10637-012-9865-z

By:

Morris, Don;
Feng, Xiaolan;
DiFrancesco, Lisa;
Fonseca, Kevin;
Forsyth, Peter;
Paterson, Alexander;
Coffey, Matt;
Thompson, Brad

Publication type:

Article

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 742, doi. 10.1007/s10637-012-9881-z

By:

Shapiro, Geoffrey;
McCallum, Stewart;
Adams, Laurel;
Sherman, Laurie;
Weller, Steve;
Swann, Suzanne;
Keer, Harold;
Miles, Dale;
Müller, Thomas;
LoRusso, Patricia

Publication type:

Article

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 623, doi. 10.1007/s10637-012-9843-5

By:

Massard, Christophe;
Margetts, Jane;
Amellal, Nadia;
Drew, Yvette;
Bahleda, Ratislav;
Stevens, Peter;
Armand, Jean;
Calvert, Hilary;
Soria, Jean;
Coronado, Cinthya;
Kahatt, Carmen;
Alfaro, Vicente;
Siguero, Mariano;
Fernández-Teruel, Carlos;
Plummer, Ruth

Publication type:

Article

A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 493, doi. 10.1007/s10637-012-9871-1

By:

Maria, Durvanei;
Souza, Jean;
Morais, Katia;
Berra, Carolina;
Zampolli, Hamilton;
Demasi, Marilene;
Simons, Simone;
Freitas Saito, Renata;
Chammas, Roger;
Chudzinski-Tavassi, Ana

Publication type:

Article

Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 545, doi. 10.1007/s10637-012-9888-5

By:

Grogan, Patrick;
Sleder, Kristina;
Samadi, Abbas;
Zhang, Huaping;
Timmermann, Barbara;
Cohen, Mark

Publication type:

Article

Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 587, doi. 10.1007/s10637-012-9902-y

By:

Felth, Jenny;
Lesiak-Mieczkowska, Karolina;
D'Arcy, Padraig;
Haglund, Caroline;
Gullbo, Joachim;
Larsson, Rolf;
Linder, Stig;
Bohlin, Lars;
Fryknäs, Mårten;
Rickardson, Linda

Publication type:

Article

A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 631, doi. 10.1007/s10637-012-9846-2

By:

Baker, A.;
Adab, K.;
Raghunand, N.;
Chow, H.;
Stratton, S.;
Squire, S.;
Boice, M.;
Pestano, L.;
Kirkpatrick, D.;
Dragovich, T.

Publication type:

Article

Metabolism of patupilone in patients with advanced solid tumor malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 605, doi. 10.1007/s10637-012-9838-2

By:

Kelly, Kevin;
Zollinger, Markus;
Lozac'h, Frédéric;
Tan, Eugene;
Mita, Alain;
Waldmeier, Felix;
Urban, Patrick;
Anand, Suraj;
Wang, Yanfeng;
Swart, Piet;
Takimoto, Chris;
Mita, Monica

Publication type:

Article

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 760, doi. 10.1007/s10637-012-9869-8

By:

Pienta, Kenneth;
Machiels, Jean-Pascal;
Schrijvers, Dirk;
Alekseev, Boris;
Shkolnik, Mikhail;
Crabb, Simon;
Li, Susan;
Seetharam, Shobha;
Puchalski, Thomas;
Takimoto, Chris;
Elsayed, Yusri;
Dawkins, Fitzroy;
Bono, Johann

Publication type:

Article

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 787, doi. 10.1007/s10637-013-9927-x

By:

Fischer, Alyssa;
Wu, Shenhong;
Ho, Alan;
Lacouture, Mario

Publication type:

Article

Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 677, doi. 10.1007/s10637-012-9860-4

By:

Asahina, Hajime;
Nokihara, Hiroshi;
Yamamoto, Noboru;
Yamada, Yasuhide;
Tamura, Yosuke;
Honda, Kazunori;
Seki, Yoshitaka;
Tanabe, Yuko;
Shimada, Hitoshi;
Shi, Xiaojin;
Tamura, Tomohide

Publication type:

Article

Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.

Published in:

2013

By:

Massard, Christophe;
Margetts, Jane;
Amellal, Nadia;
Drew, Yvette;
Bahleda, Ratislav;
Stephens, Peter;
Armand, Jean;
Calvert, Hilary;
Soria, Jean;
Coronado, Cinthya;
Kahatt, Carmen;
Alfaro, Vicente;
Siguero, Mariano;
Fernández-Teruel, Carlos;
Plummer, Ruth

Publication type:

Correction Notice

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 661, doi. 10.1007/s10637-012-9856-0

By:

Hartmann, J.;
Kollmannsberger, C.;
Cascorbi, I.;
Mayer, F.;
Schittenhelm, M.;
Heeger, S.;
Bokemeyer, C.

Publication type:

Article

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 724, doi. 10.1007/s10637-012-9878-7

By:

Delord, J.;
Ravaud, A.;
Bennouna, J.;
Fumoleau, P.;
Favrel, S.;
Pinel, M.;
Ferré, P.;
Saliba, F.

Publication type:

Article

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 3, p. 769, doi. 10.1007/s10637-012-9897-4

By:

Gangadhar, Tara;
Clark, Joseph;
Karrison, Theodore;
Gajewski, Thomas

Publication type:

Article